Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases - Quiz - MDSpire

Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases

  • By

  • Nicole Neurath

  • Andre Jefremow

  • Selina Sitte

  • Hady Haririan

  • Raja Atreya

  • Marco Kesting

  • June 29, 2026

  • 0 min

Share

Original Source(s)

Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases

  • by Nicole Neurath, Andre Jefremow, Selina Sitte, Hady Haririan, Raja Atreya, Marco Kesting

  • June 29, 2026

Related Content

UCI Health hosts IBD transition of care open house

UCI Health hosted a World IBD Day open house designed to support young adults with inflammatory bowel disease.

  • by

  • June 19, 2026

  • 1 min
Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

Prenatal Exposure to Acid-Suppressive Medications and Incident Risk of Inflammatory Bowel Disease in Children